Jakafi and Leukaemia - a phase IV clinical study of FDA data

Summary:

Leukaemia is reported as a side effect among people who take Jakafi (ruxolitinib phosphate), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Vitamin D3, and have Polycythaemia vera.

The phase IV clinical study analyzes which people have Leukaemia when taking Jakafi. It is created by eHealthMe based on reports of 56,447 people who have side effects when taking Jakafi from the FDA, and is updated regularly.

What is Jakafi?

Jakafi has active ingredients of ruxolitinib phosphate. It is often used in primary myelofibrosis. eHealthMe is studying from 56,530 Jakafi users. Check the latest studies of Jakafi.

What is Leukaemia?

Leukaemia (blood or bone marrow cancer) is found to be associated with 582 drugs and 669 conditions by eHealthMe. Check the latest studies of Leukaemia.

On Jul, 19, 2026

56,447 people reported to have side effects when taking Jakafi.
Among them, 251 people (0.44%) have Leukaemia.

Among these 251 people:

* Approximation only. Some reports may have incomplete information.

Do you take Jakafi and have Leukaemia?

- Check whether Leukaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Jakafi:

Jakafi (56,530 reports)

Leukaemia treatments and more:

Leukaemia (15,779 reports)

How severe was Leukaemia and when was it recovered:

Leukaemia in Jakafi

Expand to all the drugs that have ingredients of ruxolitinib phosphate:

Leukaemia and drugs with ingredients of ruxolitinib phosphate (292 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Jakafi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Leukaemia:

Leukaemia (582 drugs)

Browse all the conditions that are associated with Leukaemia:

Leukaemia (669 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ruxolitinib phosphate (the active ingredients of Jakafi) and Jakafi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.